Market Research Logo

EpiCast Report: Ulcerative Colitis - Epidemiology Forecast to 2025

EpiCast Report: Ulcerative Colitis - Epidemiology Forecast to 2025

Summary

Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by long-lasting inflammation and ulcers (sores) in the lining of the digestive tract. In UC, because of an abnormal response of the body’s immune system, the lining of the colon becomes inflamed and develops tiny open sores, or ulcers, that produce pus and mucous. This causes abdominal discomfort and frequent emptying of the colon. There is no cure for UC except surgical removal of the colon, but medications can help curb the inflammatory response and symptoms. UC commonly affects teenagers and young adults, and can result in poor development and growth; nonetheless, the disease can also occur in children and older individuals.

In the 7MM, GlobalData epidemiologists forecast that the diagnosed incident cases of UC will increase from 86,509 cases in 2015 to 95,864 cases in 2025, at an annual growth rate (AGR) of 1.08%. The US will have the highest number of diagnosed incident cases of UC over the forecast period, while Spain will have the lowest.

In the 7MM, GlobalData epidemiologists forecast that the diagnosed prevalent cases of UC will increase from 1,628,113 cases in 2015 to 1,711,603 cases in 2025, at an AGR of 0.51%. The US will have the highest number of diagnosed prevalent cases of UC over the forecast period, while Spain will have the lowest.

To forecast the diagnosed incident and diagnosed prevalent cases of UC in the 7MM, GlobalData epidemiologists used country-specific studies and peer-reviewed journals that provided age- and sex-specific diagnosed incidence and/or diagnosed prevalence of UC in the respective markets. The forecast methodology was consistent across the 7MM to allow for a meaningful comparison of the forecast incident and prevalent cases of UC across these markets.

Scope

  • The Ulcerative Colitis (UC) EpiCast Report provides an overview of the risk factors and global trends of UC in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed incident cases, diagnosed prevalent cases, undiagnosed prevalent cases, and total prevalent cases of UC segmented by sex and age in these seven markets. The diagnosed incident cases are further segmented by stage at diagnosis and severity grading. The diagnosed prevalent cases are further segmented by severity grading. Additionally, autoimmune comorbidities, colectomy due to failure of medical management, and mortality due to complications of UC among the diagnosed prevalent cases of UC are also included in this analysis. Furthermore, the report includes diagnosed incident cases and diagnosed prevalent cases of indeterminate colitis (IC) for both sexes and all ages in the 7MM.
  • The UC epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buyThe UC EpiCast report will allow you to -
  • Develop business strategies by understanding the trends shaping and driving the global UC market.
  • Quantify patient populations in the global UC market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for UC therapeutics in each of the markets covered.
  • Identify the percentage of diagnosed incident cases of UC by stage at diagnosis and severity grading.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Epidemiology
2.1 Disease Background
2.2 Risk Factors and Comorbidities
2.3 Global Trends
2.3.1 Incidence
2.3.2 Prevalence
2.4 Forecast Methodology
2.4.1 Sources Used
2.4.2 Forecast Assumptions and Methods
2.4.3 Sources Not Used
2.5 Epidemiological Forecast for UC (2015-2025)
2.5.1 Diagnosed Incident Cases of UC
2.5.2 Diagnosed Prevalent Cases of UC
2.5.3 Undiagnosed Prevalent Cases of UC
2.5.4 Total Prevalent Cases of UC
2.5.5 Diagnosed Incident Cases of IC
2.5.6 Diagnosed Prevalent Cases of IC
2.6 Discussion
2.6.1 Epidemiological Forecast Insight
2.6.2 Limitations of the Analysis
2.6.3 Strengths of the Analysis
3 Appendix
3.1 Bibliography
3.2 Physicians and Specialists Included in this Study
3.3 About the Authors
3.3.1 Epidemiologists
3.3.2 Reviewers
3.3.3 Global Director of Therapy Analysis and Epidemiology
3.4 About GlobalData
3.5 About EpiCast
3.6 Disclaimer
1.1 List of Tables
Table 1: Risk Factors and Comorbidities for UC and IBD
Table 2: Incidence of UC in the 5EU
Table 3: Prevalence of UC in Italy, Spain, and the UK
Table 4: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of UC
Table 5: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of UC
Table 6: 7MM, Sources Used to Forecast Undiagnosed Prevalent Cases of UC
Table 7: 7MM, Sources Used to Forecast the Total Prevalent Cases of UC
Table 8: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of UC by Stage at Diagnosis
Table 9: 7MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Incident/Prevalent Cases of UC by Severity
Table 10: 7MM, Sources of Epidemiological Data used to Forecast Mortality Due to CRC and TMC Among the Diagnosed Prevalent Cases of UC
Table 11: 7MM, Sources Used to Forecast Autoimmune Comorbidities Among the Diagnosed Prevalent Cases of UC
Table 12: 7MM, Sources Used to Forecast UC Cases Requiring Colectomy Among the Diagnosed Prevalent Cases of UC Due to Failure of Medical Management
Table 13: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of IC
Table 14: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of IC
Table 15: 7MM, Sources Not Used in Epidemiological Analysis of UC
Table 16: 7MM, Diagnosed Incident Cases of UC, Both Sexes, All Ages, N, Selected Years 2015-2025
Table 17: 7MM, Age-Specific Diagnosed Incident Cases of UC, Both Sexes, N (Row %), 2015
Table 18: 7MM, Sex-Specific Diagnosed Incident Cases of UC, All Ages, N (Row %), 2015
Table 19: 7MM, Diagnosed Prevalent Cases of UC, Both Sexes, All Ages, N, Selected Years, 2015-2025
Table 20: 7MM, Age-Specific Diagnosed Prevalent Cases of UC, Both Sexes, N (Row %), 2015
Table 21: 7MM, Sex-Specific Diagnosed Prevalent Cases of UC, All Ages, N (Row %), 2015
Table 22: 7MM, Undiagnosed Prevalent Cases of UC, Both Sexes, All Ages, N, Select Years, 2015-2025
Table 23: 7MM, Age-Specific Undiagnosed Prevalent Cases of UC, Both Sexes, N (Row %), 2015
Table 24: 7MM, Sex-Specific Undiagnosed Prevalent Cases of UC, All Ages, N (Row %), 2015
Table 25: 7MM, Total Prevalent Cases of UC, Both Sexes, All Ages, N, Selected Years, 2015-2025
Table 26: 7MM, Age-Specific Total Prevalent Cases of UC, Both Sexes, N (Row %), 2015
Table 27: 7MM, Sex-Specific Total Prevalent Cases of UC, All Ages, N (Row %), 2015
Table 28: 7MM, Diagnosed Incident Cases of IC, Both Sexes, All Ages, N, Selected Years, 2015-2025
Table 29: 7MM, Diagnosed Prevalent Cases of IC, Both Sexes, All Ages, N, Selected Years, 2015-2025
1.2 List of Figures
Figure 1: 7MM, Diagnosed Incident Cases of UC, Both Sexes, All Ages, Selected Years, 2015-2025
Figure 2: 7MM, Age-Specific Diagnosed Incident Cases of UC, Both Sexes, All Ages, N, 2015
Figure 3: 7MM, Sex-Specific Diagnosed Incident Cases of UC, All Ages, N, 2015
Figure 4: 7MM, Age-Standardized Diagnosed Incidence of UC (Cases per 100,000 Population), All Ages, Both Sexes, N, 2015
Figure 5: 7MM, Diagnosed Incident Cases of UC Segmented by Stage at Diagnosis, Both Sexes, All Ages, N, 2015
Figure 6: 7MM, Diagnosed Incident Cases of UC Segmented by Severity, Both Sexes, All ages, N, 2015
Figure 7: 7MM, Diagnosed Prevalent Cases of UC, Both Sexes, All Ages, Selected Years, 2015-2025
Figure 8: 7MM, Age-Specific Diagnosed Prevalent Cases of UC, Both Sexes, N, 2015
Figure 9: 7MM, Sex-Specific Diagnosed Prevalent Cases of UC, All Ages, N, 2015
Figure 10: 7MM, Age-Standardized Diagnosed Prevalence of UC, All Ages, Both Sexes, %, 2015
Figure 11: 7MM, Diagnosed Prevalent Cases of UC Segmented by Severity, Both Cases, All Ages, N, 2015
Figure 12: 7MM, Mortality Due to Complications Among the Diagnosed Prevalent Cases of UC, Both Sexes, All Ages, N, 2015
Figure 13: 7MM, Colectomy Due to Failure of Medical Management Among the Diagnosed Prevalent Cases of UC, Both Sexes, All Ages, N, 2015
Figure 14: 7MM. Comorbidities Among the Diagnosed Prevalent Cases of UC, Both Sexes, All Ages, N, 2015
Figure 15: 7MM, Undiagnosed Prevalent Cases of UC, Both Sexes, All Ages, Selected Years, N, 2015-2025
Figure 16: 7MM, Age-Specific Undiagnosed Prevalent Cases of UC, Both Sexes, N, 2015
Figure 17: 7MM, Sex-Specific Undiagnosed Prevalent Cases of UC, All Ages, N, 2015
Figure 18: 7MM, Age-Standardized Undiagnosed Prevalence of UC, All Ages, Both Sexes, %, 2015
Figure 19: 7MM, Total Prevalent Cases of UC, Both Sexes, All Ages, Selected Years, N, 2015-2025
Figure 20: 7MM, Age-Specific Total Prevalent Cases of UC, Both Sexes, N, 2015
Figure 21: 7MM, Sex-Specific Total Prevalent Cases of UC, All Ages, N, 2015
Figure 22: 7MM, Age-Standardized Total Prevalence of UC, All Ages, Both Sexes, %, 2015
Figure 23: 7MM, Diagnosed Incident Cases of IC, Both Sexes, All Ages, Selected Years, N, 2015-2025
Figure 24: 7MM, Diagnosed Prevalent Cases of IC, Both Sexes, All Ages, Selected Years, N, 2015-2025

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report